Nicotinamide Adenine Dinucleotide and Skeletal Muscle Metabolic Phenotype — NADMet  

Aging Clinical Trial

Official title: Nicotinamide Adenine Dinucleotide and Skeletal Muscle Metabolic Phenotype (NADMet)

Status Recruiting

Clinical Trial Summary

This study is designed to assess the physiological consequences of elevating Nicotinamide Adenine Dinucleotide (NAD+) availability using Nicotinamide Riboside (NR) supplementation in skeletal muscle tissue, and examine its effect upon muscle metabolic phenotype.

Clinical Trial Description

-NAD+ sensitive metabolic decline in ageing, including sarcopenia, leads to a reduction in energy metabolism, contribute to chronic inflammation, disposing individuals to metabolic disease and overall decreased later-life health. Prominent metabolic changes include a decline in NAD+ content and deterioration in muscle NAD+ mediated signalling and mitochondrial function, ultimately compromising skeletal muscle and whole body energy homeostasis.

The most efficient means to boost NAD+ in muscle appears to be oral delivery of NR, and participants will be supplemented with 1000mg NR (2x x250mg tablets twice daily) for 3 weeks.

• Hypothesis: elevating skeletal muscle NAD+ bioavailability using NR supplementation will increase markers of mitochondrial function and that will manifest as a more favourable metabolic profile.

• Study Setting: the study will be carried out at the NIHR/Wellcome Trust Clinical Research Facility, Queen Elizabeth Hospital Birmingham. ;

Related Conditions & MeSH terms

• Aging

• NCT number: NCT02950441
• Study type: Interventional
• Source: University of Birmingham
• Contact: Yasir Elhassan, MRCP
• Phone: +441214158705
• Email: y.mohamedelhassan@bham.ac.uk
• Status: Recruiting
• Phase: Phase 2
• Start date: June 2016
• Completion date: September 2019